Zhongshan City People's Hospital on March 20 issued the city's first prescription for the Florbetaben F 18 injection, a new molecular targeted diagnostic drug for Alzheimer's disease (AD).

A patient received the injection and underwent a non-invasive Aβ-PET/CT imaging examination at the hospital. She becomes the first in Zhongshan to use this drug since it was approved for marketing in China.

The non-invasive Aβ-PET/CT imaging examination is able to detect pathological changes of AD 15 to 20 years in advance, which is conducive to early and precise treatment for patients.